Efficacy of Growth Hormone Treatment in Children With Chronic Kidney Disease: Tunisian Experience.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a controlled clinical trial.

To study the effect of using recombinant human growth hormone (rhGH) in growth retarded children with chronic kidney disease (CKD).

Who Took Part

The abstract describes 2 children taking part.

By PubMed's age tags, the people studied were children.

Children were divided into rhGH-treated or non-rhGH treated groups.

What Was Measured

The subject headings attached to it are Body Height, Growth Disorders, Growth Hormone, Human Growth Hormone, Kidney Failure, Chronic and Renal Insufficiency, Chronic.

What This Means in Plain Language

This is a controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 2 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Indian pediatrics), a journal based in India.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.